Piper Sandler cuts Merit Medical stock price target on valuation
Piper Sandler has cut its price target on Merit Medical Systems (NASDAQ: MMSI) to $106 from $113, while maintaining an Overweight rating. The firm anticipates a potential upside in gross margin percentage and expects conservative guidance from management to lead to higher Street estimates. Despite trading at a high P/E, InvestingPro's Fair Value assessment suggests the stock is undervalued, and recent developments include new board leadership and analyst coverage from BTIG.
Piper Sandler cuts Merit Medical stock price target on valuation
Piper Sandler has reduced its price target for Merit Medical Systems (NASDAQ:MMSI) from $113 to $106, while maintaining an Overweight rating, citing valuation concerns. The stock is currently trading near its 52-week low, and investors await its earnings report on February 24 to confirm revenue growth and assess management's conservative guidance. Despite a high P/E ratio, InvestingPro's Fair Value assessment suggests the stock is undervalued, supported by strong liquid assets.
Merit Medical Systems (MMSI) Expected to Announce Quarterly Earnings on Tuesday
Merit Medical Systems (MMSI) is scheduled to release its Q4 2025 earnings after market close on Tuesday, February 24th, with analysts projecting earnings of $0.96 per share and revenue of $390.77 million. Insiders have recently sold shares, though major institutional investors maintain significant holdings. The stock currently trades near $81.66, and analysts maintain a "Moderate Buy" rating with an average target price of $106.00.
Trading Systems Reacting to (MMSI) Volatility
This article from Stock Traders Daily discusses the volatility of Merit Medical Systems Inc. (NASDAQ: MMSI), highlighting key findings from their AI models. It identifies a stable neutral reading in shorter horizons, a mid-channel oscillation pattern, and an exceptional risk-reward setup. The piece also details specific institutional trading strategies (Position Trading, Momentum Breakout, Risk Hedging) and multi-timeframe signal analysis for MMSI.
Envestnet Asset Management Inc. Has $22.41 Million Position in Merit Medical Systems, Inc. $MMSI
Envestnet Asset Management Inc. significantly increased its stake in Merit Medical Systems (NASDAQ:MMSI) during Q3, now holding 269,189 shares valued at $22.41 million. Institutional investors collectively own 99.66% of the stock, while analysts rate MMSI as a "Moderate Buy" with an average target price of $106. Insider selling by Chairman Fred Lampropoulos and others has occurred recently, though insiders still collectively own 3.20% of the company.
Merit Medical Systems stock hits 52-week low at $78.03
Merit Medical Systems (MMSI) stock has fallen to a 52-week low of $78.03, representing a 29% decline from its high and a 24.56% year-over-year decrease, due to market challenges and company-specific factors. Despite these setbacks—including a reimbursement delay for its WRAPSODY device and a reduced price target from Canaccord Genuity—the company maintains strong fundamentals, including a "GREAT" financial health score and 11.41% revenue growth. BTIG initiated coverage with a "Buy" rating, citing its extensive product portfolio.
Merit Medical Systems stock hits 52-week low at $78.03
Merit Medical Systems Inc. (MMSI) stock has fallen to a 52-week low of $78.03, representing a 29% decline from its high, amidst challenging market conditions and a significant 1-year total return of -24.56%. Despite this, the company maintains strong fundamentals, including a "GREAT" financial health score, a high current ratio, and 11.41% revenue growth, with analysts projecting continued profitability. Recent developments include the withdrawal of a Medicare payment boost application for its WRAPSODY device, a lowered price target from Canaccord Genuity due to the reimbursement delay, and leadership changes at the board level.
Merit Medical Systems (MMSI) Stock Trades Up, Here Is Why
Shares of medical device company Merit Medical Systems (MMSI) rose by 3.6% following a softer-than-expected inflation report, which increased hopes for Federal Reserve interest rate cuts. The January Consumer Price Index (CPI) showed a smaller-than-forecast rise of 0.2%, with the annual rate cooling to 2.4%, suggesting potential monetary easing. This news, despite initial market volatility, was seen as significant by the market for MMSI, which had previously reported strong Q3 2025 financial results.
Merit Medical Systems (NASDAQ:MMSI) Reaches New 1-Year Low - Here's What Happened
Merit Medical Systems (NASDAQ:MMSI) recently hit a new 52-week low of $77.62, trading below its 50-day and 200-day moving averages. Despite a consensus "Moderate Buy" rating from analysts with an average target price of $106, insiders have been net sellers, contributing to recent stock pressure. The company reports strong liquidity but has a relatively high valuation, with institutional investors holding a significant stake.
Wall Street Analysts Predict a 26.82% Upside in Merit Medical (MMSI): Here's What You Should Know
Wall Street analysts are predicting a 26.82% upside for Merit Medical (MMSI), with a mean price target of $104.27. While cautioning against relying solely on price targets due to their often-optimistic nature, the article highlights a strong agreement among analysts regarding the company's earnings prospects and a positive trend in EPS estimate revisions, suggesting potential for stock appreciation. MMSI currently holds a Zacks Rank #2 (Buy), further indicating its potential.
Bessemer Group Inc. Has $16.95 Million Stock Position in Merit Medical Systems, Inc. $MMSI
Bessemer Group Inc. significantly increased its stake in Merit Medical Systems, Inc. by 160,206.3% in Q3, now holding 203,589 shares valued at $16.95 million. This comes as insider Fred P. Lampropoulos recently sold 25,000 shares. Analysts generally maintain a positive outlook with a "Moderate Buy" rating and a consensus price target of $106.00, while the stock trades near $82.50.
Merit Medical Systems (NASDAQ:MMSI) Rating Increased to Strong-Buy at BTIG Research
BTIG Research has upgraded Merit Medical Systems (NASDAQ:MMSI) to a "strong-buy" rating, with analysts setting an average price target of $106.00, suggesting a "Moderate Buy" consensus. The article highlights recent insider selling, institutional investor activity, and the company's financial performance, including its market cap and P/E ratio. Merit Medical Systems is a global manufacturer of medical devices used in diagnostic and interventional procedures.
Investing in Merit Medical Systems (NASDAQ:MMSI) Five Years Ago Would Have Delivered You a 37% Gain
Merit Medical Systems (NASDAQ:MMSI) stock has risen 37% over the past five years, underperforming the broader market. While the stock is down 24% in the last year, the company has transitioned from a loss to profitability in the last five years, with EPS growing 22% annually over the last three years, exceeding the 6% average annual share price increase in the same period. Investors are advised to consider fundamental data for long-term growth trends and potential investment risks.
A Look At Merit Medical Systems (MMSI) Valuation After Strong Q3 Beat And Cautious Full Year Guidance
Merit Medical Systems (MMSI) reported strong Q3 revenue growth of 13% year-on-year, surpassing analyst estimates, but issued a cautious full-year guidance. Despite a recent share price decline, Simply Wall St's analysis suggests MMSI is undervalued by 20.3% with a fair value of $103.55, based on future earnings potential and expected growth in cardiovascular and endoscopy segments. However, the current P/E ratio of 41.3x is higher than industry averages, prompting a question of whether future optimism is already baked into the price.
BTIG Initiates Coverage of Merit Medical Systems (MMSI) with Buy Recommendation
BTIG has initiated coverage of Merit Medical Systems (MMSI) with a Buy recommendation. Analysts project an average one-year price target of $106.45, representing a potential 33.68% upside from its current price. The article also notes a decrease in institutional ownership but a bullish outlook indicated by the put/call ratio.
Merit Medical Systems stock initiated with Buy rating by BTIG
BTIG initiated coverage on Merit Medical Systems (NASDAQ:MMSI) with a Buy rating and a $107 price target, noting the company's extensive product portfolio, long history, and strategic growth through organic expansion and acquisitions. The stock is currently trading significantly below BTIG's target and near its 52-week low. Despite a recent setback with the withdrawal of a WRAPSODY product application, the firm believes Merit's core markets will remain strong due to rising cardiovascular disease prevalence.
This Merit Medical Systems Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday
This article highlights two analyst initiations for Friday. BTIG analyst Sam Eiber initiated coverage on Merit Medical Systems, Inc. (NASDAQ: MMSI) with a Buy rating and a $107 price target. Additionally, HC Wainwright & Co. analyst Heiko F. Ihle initiated coverage on Titan Mining Corporation (AMEX: TII) with a Buy rating and a $6.5 price target.
Merit Medical Systems (MMSI) Receives "Buy" Rating from BTIG | M
BTIG has initiated coverage on Merit Medical Systems (MMSI) with a "Buy" rating and a price target of $107.00 USD. This follows several other analyst ratings, including a reiteration of "Buy" from Needham and an "Overweight" from Wells Fargo, although some recent price targets were lowered. The average target price from 11 analysts is $104.36, suggesting a potential upside of 31.08% from its current price.
Merit Medical Systems stock initiated with Buy rating by BTIG
BTIG initiated coverage of Merit Medical Systems (NASDAQ:MMSI) with a Buy rating and a $107 price target, citing the company's strong product portfolio, deep integration into customer supply chains, and potential for growth through organic expansion and acquisitions. The firm highlighted the new CEO and the focus on higher-growth therapeutic products, such as Wrapsody. Merely Medical recently appointed F. Ann Millner as the new Chair of the Board and withdrew an application for federal payment for its WRAPSODY device, leading Canaccord Genuity to lower its price target but maintain a Buy rating.
Spotting Winners: Merit Medical Systems (NASDAQ:MMSI) And Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks In Q3
This article analyzes the Q3 performance of Merit Medical Systems (MMSI) and other medical devices and supplies companies in the cardiology, neurology, and vascular sectors. It highlights that the industry experienced strong Q3 results with revenues beating estimates and stock prices performing well post-earnings. While Merit Medical Systems delivered a strong quarter, it provided the weakest full-year guidance among its peers, in contrast to ICU Medical which showed the strongest performance against analyst estimates.
Spotting Winners: Merit Medical Systems (NASDAQ:MMSI) And Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks In Q3
This article analyzes the Q3 performance of Merit Medical Systems (NASDAQ:MMSI) and its peers in the medical devices & supplies sector for cardiology, neurology, and vascular care. It highlights Merit Medical Systems' strong revenue beat but weakest full-year guidance among the group, contrasting it with ICU Medical's strong performance and Artivion's weaker results against estimates. The article also touches upon Penumbra's strong Q3 and discusses the industry's opportunities with aging populations and technological advancements, alongside challenges like high R&D costs and regulatory pressures.
How Merit Medical Systems Inc. (MMSI) Affects Rotational Strategy Timing
This article analyzes Merit Medical Systems Inc. (MMSI) through the lens of a rotational trading strategy, highlighting near-term neutral sentiment and existing weakness in mid- and long-term outlooks. It presents three AI-generated institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis, showing support and resistance levels for various time horizons.
Great Lakes Advisors LLC Cuts Stock Position in Merit Medical Systems, Inc. $MMSI
Great Lakes Advisors LLC has significantly reduced its stake in Merit Medical Systems (NASDAQ:MMSI) by 96%, selling over 107,000 shares in Q3 and retaining only 4,503 shares valued at $375,000. Despite this, other institutional investors have either purchased new stakes or increased their holdings in the medical instruments supplier. The stock currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $105.88, suggesting potential upside from its current trading price of around $81.61.
Thrivent Financial for Lutherans Has $62.43 Million Stock Holdings in Merit Medical Systems, Inc. $MMSI
Thrivent Financial for Lutherans significantly increased its stake in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 250.5% in the third quarter, now holding 750,066 shares valued at approximately $62.43 million. This makes Thrivent Financial for Lutherans a 1.27% owner of the medical instruments supplier. Merit Medical Systems exceeded Q3 earnings expectations with an EPS of $0.92 against an estimated $0.82, and revenue grew by 13% year-over-year to $384.2 million.
Y Intercept Hong Kong Ltd Makes New Investment in Merit Medical Systems, Inc. $MMSI
Y Intercept Hong Kong Ltd has acquired a new stake of 25,379 shares in Merit Medical Systems (NASDAQ:MMSI), valued at approximately $2.11 million during Q3. Despite insider sales totaling 60,000 shares in the last 90 days, Merit Medical Systems exceeded Q3 earnings estimates with EPS of $0.92 and revenue of $384.16 million, leading analysts to maintain a "Moderate Buy" rating with a target price of $105.88.
Assessing Merit Medical Systems (MMSI) Valuation After Bullish Analyst Reactions To Earnings Beats
Merit Medical Systems (MMSI) has seen bullish analyst reactions due to earnings beats, strong free cash flow, and a solid balance sheet, yet its share price has recently declined. Despite a narrative fair value suggesting it is 22.3% undervalued at $103.55, its current P/E ratio of 40.3x is significantly higher than the industry average, posing a risk if earnings falter. The valuation hinges on factors like timely reimbursement for WRAPSODY CIE and stabilizing China revenue.
Merit Medical Stock Soars After Hours As Better-Than-Expected Q2 Guidance Outweighs CEO Exit
Merit Medical Systems' stock rose significantly after announcing better-than-expected Q2 guidance, which overshadowed the news of CEO Fred Lampropoulos's planned retirement in May 2027. The company's strong financial outlook and strategic growth initiatives appear to reassure investors despite the upcoming leadership change.
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
Merit Medical Systems, Inc. (MMSI) is recommended as a strong buy due to its robust product portfolio, including the WRAPSODY CIE and an expanding high-margin product line, and strong free cash flow generation. Despite potential headwinds like reimbursement uncertainty and macroeconomic volatility, the company shows a positive estimate revision trend for 2026, with an impressive average earnings surprise of 14.1% over the past four quarters.
Why Merit Medical (MMSI) is Poised to Beat Earnings Estimates Again
Merit Medical (MMSI) is anticipated to beat its upcoming earnings estimates, continuing a strong trend from previous reports. The company has a history of exceeding earnings expectations, with an average surprise of 14.82% over the last two quarters. This positive outlook is further supported by the stock's positive Zacks Earnings ESP and a Zacks Rank #2 (Buy), indicating a high probability of another earnings beat.
(MMSI) and the Role of Price-Sensitive Allocations
This article analyzes Merit Medical Systems Inc. (NASDAQ: MMSI), highlighting a strong near-term sentiment while mid and long-term sentiments remain weak. It identifies a key support test for the stock and an exceptional risk-reward setup targeting a 7.9% gain. The piece also outlines three AI-generated institutional trading strategies tailored for different risk profiles and holding periods.
Mountain Pacific Investment Advisers LLC Has $570,000 Stake in Merit Medical Systems, Inc. $MMSI
Mountain Pacific Investment Advisers LLC significantly reduced its stake in Merit Medical Systems, Inc. by 92.7% in Q3, now holding 6,848 shares valued at $570,000. Despite this, other institutional investors increased their positions, and Merit Medical Systems reported strong Q3 earnings, beating analyst estimates with $0.92 EPS and $384.16 million in revenue. Analysts maintain a "Moderate Buy" rating for MMSI with a consensus target price of $105.88, even as company insiders have sold shares totaling over $5 million in the last three months.
Investors in Merit Medical Systems (NASDAQ:MMSI) have seen notable returns of 43% over the past five years
Merit Medical Systems (NASDAQ:MMSI) shareholders have experienced a 43% return over the past five years, underperforming the broader market. The stock is down 20% in the last year, suggesting investor caution despite the company transitioning from a loss to profitability. The company's EPS growth of 22% annually over three years outpaces its 6% share price increase during the same period, indicating a potential undervaluation by the market.
A Look At Merit Medical Systems (MMSI) Valuation As M&A Becomes A Key Growth Focus
Merit Medical Systems (MMSI) is focusing on mergers and acquisitions as a key growth strategy, supported by a growing cash reserve. Despite a recent 20% decline in stock value over the past year, longer-term shareholder returns are positive, and the company is considered undervalued by its narrative fair value of US$103.55, compared to its current price of US$82.31. However, its P/E ratio of 41.2x suggests the market might be overpaying for its growth prospects.
EULAV Asset Management Buys 41,000 Shares of Merit Medical Systems, Inc. $MMSI
EULAV Asset Management significantly increased its stake in Merit Medical Systems (MMSI) by 35% in the third quarter, purchasing an additional 41,000 shares. This brings their total holding to 158,000 shares, valued at approximately $13.15 million, representing about 0.27% of the company. Despite insider selling, Merit Medical Systems demonstrated strong third-quarter results, beating EPS and revenue estimates, and maintains a "Moderate Buy" analyst rating with an average price target of $105.88.
Assessing Merit Medical Systems (MMSI) Valuation After Board Chair Transition And Recent Share Price Strength
Merit Medical Systems (MMSI) is under evaluation after a board chair transition, with F. Ann Millner appointed as Chair. The stock has seen significant short-term gains but a decline over the past year, while long-term returns remain strong. Analysts suggest the stock is undervalued, though its high P/E ratio compared to peers raises concerns about its valuation.
Does Merit Medical Systems' (MMSI) New Revenue Guide and Chair Signal a Strategic Shift in Priorities?
Merit Medical Systems (MMSI) recently issued fourth-quarter 2025 revenue guidance between US$389,000,000 and US$395,000,000 and announced a Board leadership change, with F. Ann Millner appointed Chair. This signals a closer look into how the company balances its growth aspirations with governance continuity. The article emphasizes that while the revenue outlook is crucial for assessing how investments translate to top-line growth, investors should remain aware of potential risks.
Responsive Playbooks and the MMSI Inflection
This article analyzes Merit Medical Systems Inc. (NASDAQ: MMSI) with a focus on near-term weak sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward setup. It outlines three distinct AI-generated trading strategies—position, momentum breakout, and risk hedging—tailored for different risk profiles. The analysis also provides multi-timeframe signal analysis, including support and resistance levels for MMSI.
Merit Medical stock slides 7% after board shake-up and early Q4 revenue range — what to watch next
Merit Medical Systems Inc. shares dropped 7.3% on Friday following news of a leadership transition and preliminary Q4 revenue figures. The company reported unaudited revenue between $389 million and $395 million for the quarter, an approximate 10-11% increase year-over-year. Investors are now focused on the full Q4 and full-year 2025 results and the fiscal 2026 guidance, which will be released on February 24th.
Piper Sandler Maintains Merit Medical Systems(MMSI.US) With Buy Rating, Maintains Target Price $109
Piper Sandler analyst Jason Bednar has reiterated a Buy rating for Merit Medical Systems (MMSI.US), maintaining a target price of $109. Bednar's previous year-long performance indicates a 39.9% success rate and an average return of -5.0% based on TipRanks data. The article emphasizes that this information is for educational purposes and not investment advice.
Merit Medical Stock (-7.3%): Founder's Exit Sparks Distribution
Merit Medical stock experienced a significant drop of 7.3% following the departure of its founder. This event has led to a distribution, prompting investors to reassess the company's future performance. The article suggests that the exit of key personnel can have a substantial impact on stock value and market perception.
Merit Medical (MMSI) stock slides 8% as founder exits chair role and early Q4 revenue lands
Merit Medical (MMSI) stock fell approximately 8% after the company announced its founder resigned from his director and chair roles, and released preliminary Q4 revenue figures. While the Q4 revenue projection of $389 million-$395 million was slightly above consensus, investors are awaiting full results and fiscal 2026 guidance on February 24. A Needham analyst maintained a Buy rating, citing the better-than-expected preliminary revenue.
Neil Peterson, COO of Merit Medical, sells $450k in MMSI stock
Merit Medical Systems Inc.'s COO, Neil Peterson, sold 5,000 shares of MMSI stock for $450,000 and exercised options to acquire 5,000 shares for $272,000. These transactions were performed under a prearranged Rule 10b5-1 trading plan. This news follows the deferral of the company's WRAPSODY Cell-Impermeable Endoprosthesis application by CMS and positive 24-month study results for the WRAPSODY device in dialysis patients.
Merit Medical Appoints F. Ann Millner as Chair of the Board and Announces Projected Preliminary Unaudited Revenue Results for the Fourth Quarter of 2025
Merit Medical Systems, Inc. announced the unanimous appointment of F. Ann Millner, Ed.D., as the new Chair of the Board, effective January 5, 2026, succeeding Fred P. Lampropoulos who resigned after 38 years with the company. The company also projected preliminary unaudited revenue for the fourth quarter of 2025 to be between $389 million and $395 million, marking a 10% to 11% increase year-over-year. Merit Medical plans to release its full financial results and fiscal year 2026 guidance on February 24, 2026.
After 38 years, company founder hands over board role as sales climb
Merit Medical Systems, Inc. (NASDAQ: MMSI) has appointed F. Ann Millner as the new Chair of its Board of Directors, effective January 5, 2026, following the resignation of founder Fred P. Lampropoulos. The company also announced strong preliminary unaudited fourth-quarter 2025 revenues, projected to be between $389 million and $395 million, marking a 10%-11% year-over-year increase. Lampropoulos, who founded the company 38 years ago, will continue to provide consulting services until March 31, 2026.
Merit Medical Systems announces new board chair appointment
Merit Medical Systems appointed F. Ann Millner as the new Chair of its Board, following the resignation of founder Fred P. Lampropoulos. This leadership change occurred while the company reported strong preliminary unaudited fourth-quarter 2025 revenue, showing a 10-11% year-over-year increase. Analysts currently rate MMSI stock as a Buy with a $99.00 price target, although TipRanks' AI Analyst suggests a Neutral stance due to high valuation despite robust financial performance.
Merit Medical (MMSI) Reports Strong Preliminary Q4 2025 Revenue Growth
Merit Medical Systems (MMSI) announced strong preliminary unaudited revenue for Q4 2025, projecting between $389 million and $395 million, representing a 10% to 11% growth year-over-year. The company, which specializes in medical devices for interventional cardiology, radiology, and endoscopy, demonstrates robust financial health with consistent revenue growth, efficient operating margins, and a strong balance sheet. Despite some insider selling, analyst sentiment remains positive, though the stock's RSI suggests it is approaching overbought territory.
Merit Medical Systems Announces Board Changes
Merit Medical Systems announced that Fred P. Lampropoulos resigned as a director and Chair of the Board for personal reasons, effective January 4, 2026. Following his departure, F. Ann Millner, Ed.D., was appointed as the new Chair of the Board, effective January 5, 2026. This change in leadership was detailed in an SEC filing on January 8, 2026.
Neil Peterson, COO of Merit Medical, sells $450k in MMSI stock
Neil Peterson, COO of Merit Medical Systems Inc (MMSI), sold 5,000 shares of company stock for $450,000 on January 6, 2026, after exercising options for 5,000 shares. These transactions were part of a prearranged trading plan. In other news, CMS deferred Merit Medical's application for transitional payment for its WRAPSODY device, leading to the company withdrawing the application, while an analyst lowered the price target but maintained a "Buy" rating.
Does Merit Medical Systems (NASDAQ:MMSI) Have A Healthy Balance Sheet?
Merit Medical Systems (NASDAQ:MMSI) appears to have a healthy balance sheet, managing its debt prudently. The company's net debt is only 1.2 times its EBITDA, and its EBIT covers interest expenses by 14.1 times. Additionally, Merit Medical Systems' EBIT grew by 10% last year, and its free cash flow is a strong 98% of EBIT, indicating a robust ability to manage its financial obligations.
Merit Medical Systems, Inc. (MMSI) Stock Analysis: A 19.84% Upside Potential Amid Strong Buy Ratings
Merit Medical Systems, Inc. (MMSI) is highlighted as an attractive investment in the medical instruments sector. Analysts have given the stock strong buy ratings, projecting a potential upside of 19.84%, with an average target price of $103.60. The company demonstrates robust financial performance with 13.00% revenue growth and impressive free cash flow, reinvesting earnings for future expansion.
